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Introduction: Post-stereotactic radiation-induced neoplasms, although relatively rare, have raised the question of
benefit regarding CyberKnifeW treatments versus the risk of a secondary malignancy. The incidence of such
neoplasms arising in the nervous system is thought to be low, given the paucity of case reports regarding such
secondary lesions.
Case presentation: Here we describe a case of a 43-year-old Middle Eastern woman with primary clear cell renal
cell carcinoma and a metastatic focus to the left brain parenchyma who presented with focal neurologic deficits.
Following post-surgical stereotactic radiation in the region of the brain metastasis, the patient developed a
secondary high-grade astrocytoma nearly 5 years after the initial treatment.
Conclusion: Although the benefit of CyberKnifeW radiotherapy treatments continues to outweigh the relatively low
risk of a radiation-induced secondary malignancy, knowledge of such risks and a review of the literature are
warranted.Introduction
Given the advent of new stereotactic radiosurgery tech-
niques, important questions have arisen regarding the
risk of secondary malignancy following such treatments.
On the basis of previous case reports, the incidence of
such a secondary malignancy following CyberKnifeW
therapy has been estimated at between 0.7% and 1.9%
[1,2]. Specifically, reports of post- stereotactic radiation-
induced central nervous system (CNS) tumors have been
few, and reflect a higher incidence in patients with a pre-
disposition to cancer, such as those with neurofibroma-
tosis. Typically, such a secondary malignancy is thought
to arise within a period of 5 to 10 years post-treatment,
given a review of the literature involving such patients.
Here we present a case of radiation-induced glioma in a
patient following treatment with stereotactic radiosur-
gery for a metastatic renal cell carcinoma focus to the
brain. It should be noted that although there remains a
notable risk of developing a secondary CNS malignancy
following radiotherapy treatment, it is thought that the* Correspondence: Malak_abed@hotmail.com
Pathology Department, Georgetown University Hospital, Washington, DC
20007, USA
© 2012 Abedalthagafi and Bakhshwin; licensee
of the Creative Commons Attribution License
distribution, and reproduction in any mediumoverall benefits of such treatments outweigh the risk of
developing a secondary neoplasm.Case presentation
A 43-year-old Middle Eastern woman originally pre-
sented complaining of a sudden onset of right upper ex-
tremity weakness and numbness. A magnetic resonance
imaging (MRI) scan of her brain demonstrated a lesion
in the left frontal lobe consistent with a possible metas-
tasis, and an abdominal computed tomography showed
an 8cm mass in the right kidney. She underwent a rad-
ical laparoscopic nephrectomy a month later, and surgi-
cal pathology revealed clear cell renal cell carcinoma
(Figure 1) of Fuhrman nuclear grade 3 without evidence
of metastasis to perinephric fat, the adrenal gland, renal
vasculature, or hilar lymph nodes.
Later that same month, the patient also had a left
frontal craniotomy performed for metastatic focus resec-
tion. Microscopically, the specimen revealed nests of
large pleomorphic cells with prominent eosinophilic nu-
clei that resembled malignant ganglion cells. However,
clear cytoplasm was observed in some areas (Figure 2A).
Immunohistochemical (IHC) staining was positive forBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Microscopic image of primary renal cell carcinoma.
Hematoxylin and eosin (H&E) stain at 20× magnification.
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for glial fibrillary acidic protein (GFAP), neurofilament,
chromogranin, S100, Human Melanoma Black-45
(HMB-45), smooth muscle actin, desmin, and CD68.
The brain mass was therefore diagnosed as poorly-
differentiated grade 4 metastatic renal cell carcinoma.
Following neurosurgery, the patient underwent whole
brain radiotherapy followed by CyberKnifeW stereotactic
radiosurgery.
A year later, the patient began developing neurological
symptoms including right arm tremor, weakness, dizzi-
ness, and abnormal sensation on her right cheek. An
MRI scan of her brain revealed a large left frontal mass
stemming from the insular that subsequently enlarged
and grew upwards, creating a midline shift. After
5 months, she underwent resection of the mass. Path-
ology showed radiation necrosis with sheets of foamy
macrophages and gliosis of the surrounding brain tissue
with focal perivascular chronic inflammation. IHC stain-
ing was negative for keratin, with no evidence of viable
tumor cells. IHC staining was positive for CD68 indicat-
ing the histiocytic nature of many of the foamy cells.(A) (B
Figure 2 Microscopic images of brain metastases. (A) H&E stain at 10×The patient once again presented with right-sided
hemiparesis. Imaging studies showed a left occipital-
parietal mass, and surgical resection was completed ap-
proximately 4.5 years after her initial craniotomy and
brain irradiation. The pathologic appearance of the tissue
was consistent with a high-grade astrocytoma, probably
glioblastoma multiforme, with areas of necrosis and vas-
cular proliferation (Figures 3A and 3B). IHC was also in-
dicative of glial cells, with staining positive for GFAP and
S100 (Figure 3C) but negative for keratin (Figure 3D) and
CD10 (Figure 3E). The molecular immunology Borstel-1
(MIB-1) proliferation index was found to be 20%
(Figure 3F).
Discussion
The criteria for a radiation-induced neoplasm as origin-
ally outlined by Cahan et al. in 1948 [3] include: 1) the
tumor must not be present at the time of irradiation; 2)
there must be a prolonged latency period between radi-
ation delivery and tumor development; 3) the tumor
must arise in the irradiated region; 4) the tumor must be
histologically distinct from the original tumor; and 5)
the patient must not have a genetic predisposition to the
development of cancer. Our patient’s case seems to fulfill
all of these criteria. Extensive imaging was performed
at the time of the original diagnosis and no evidence
of a lesion was found in the left occipital-parietal area.
Although 5 years is the generally accepted minimum
latency period for developing a radiation-induced ma-
lignancy, cases with shorter latency periods have been
reported. This case is complicated by the fact that the
patient received both whole brain irradiation as well as
Gamma Knife stereosurgery, but the affected secondary
location was definitely within the irradiated field. Tu-
mor markers show the histologic disparity between the
original brain metastases and the new lesion. Finally,
the patient was not known to have any genetic condi-
tions that predispose toward carcinogenesis.
The risk of developing a secondary nervous system
cancer, particularly meningiomas, following conventional)





Figure 3 Microscopic images of radiation-induced brain tumor. (A) H&E stain at 10× magnification. (B) H&E stain at 20× magnification. (C)
S100 immunohistochemistry at 10× magnification. (D) Keratin staining at 10× magnification. (E) CD10 staining at 10× magnification. (F) Ki-67
staining at 10× magnification. (G) GFAP staining at 10× magnification.
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lished. Studies of the survivors of the atomic bombings
of Hiroshima and Nagasaki indicate an increased inci-
dence of meningiomas in this population [4-6]. Epi-
demiological data derived from child immigrants to
Israel after World War II who received radiation for the
treatment of tinea capitis showed an increase of up to
6.9-fold in nervous system neoplasms (including men-
ingiomas, gliomas, and nerve sheath tumors) [7]. There
has also been some suggestion of greater numbers of
meningiomas and gliomas in adults who underwent
radiotherapy for pituitary adenomas [8,9]. Finally,
experiments on primates given therapeutic doses of frac-
tionated whole-brain radiation resulted in high rates of
induction of glioblastoma multiforme [10], and over 100
human cases in which a glioma appeared after radiother-
apy have been identified [11]. Nevertheless, the absolute
risk of developing a radiation-induced neoplasm after re-
ceiving radiotherapy to the CNS remains relatively low
and it is generally thought that the overall benefits of
the treatment outweigh the negative complication rate
of alternative treatments [12].
The risk of oncogenesis due to stereotactic radiosur-
gery has generally been believed to be lower than that of
conventional radiotherapy. Although traditional prac-
tices involve low-dose radiation delivered to a high vol-
ume of tissue, stereotactic methods allow for high-dose,low-volume radiation with a steep drop in dosage out-
side the targeted zone. The perception of increased
safety in radiosurgery has been supported by an analysis
of nearly 5000 English patients who underwent Gamma
Knife therapy [13]. This study found only one new case
of astrocytoma following radiation in comparison to a
predicted incidence of 2.47 in the general population. A
major criticism of the study has been that the mean
follow-up interval was only just over 6 years. However,
the follow-up of over 1200 of the patients was greater
than 10 years.Conclusions
As yet, relatively few case reports of post-stereotactic ra-
diation-induced nervous system tumors have been docu-
mented in the literature (Table 1), and some of these
involve patients with a genetic predisposition to cancer
(e.g. neurofibromatosis 2) who thus do not completely
fulfill the Cahan [3] criteria. On the basis of these re-
ports, the incidence of a secondary malignancy following
stereotactic radiosurgery has been estimated at between
0.7% and 1.9% [1,2]. In addition, it is believed that, due
to the relatively recent advent and dissemination of this
technology, relatively more cases may be identified in
the near future as a greater population of treated pa-
tients reaches the most dangerous latency interval.











Comey 1998 [14] 44M VS Cerebellopontine angle 5 years Triton tumor Cerebellopontine angle
Noren 1998 [15] 18Fb VS Cerebellopontine angle 6 years Triton tumor Cerebellopontine angle
Thomsen 2000 [16] 19Fb VS Cerebellopontine angle 6 years Meningosarcoma Cerebellopontine angle
Yu 2000 [17] 70F Meningioma Occipital region 7 years GBM Occipital lobe
Kaido 2001 [18] 20M AVM Right parietal lobe 6.5 years GBM Right parietal lobe
Shamisa 2001 [19] 57F VS Cerebellopontine angle 7.5 years GBM Inferior temporal lobe
Bari 2002 [20] 30Fb VS Cerebellopontine angle 3.5 years Malignant nerve
sheath tumor
Cerebellopontine angle
Salvati 2003 [11] 66F Cavernoma Right frontal region 13 years GBM Right frontal,
corpus callosum











Sanno 2004 [23] 53F Meningioma Falx cerebri 5 years Osteosarcoma Right parietal lobe









64Fb AVM Cerebellopontine angle 5 years GBM Right temporal lobe
Berman 2007 [25] 34F AVM Pineal region 9 years GBM Corpus callosum and/or
right parietal lobe




aage at time of radiation.
bpatient with neurofibromatosis 2.
Abbreviations: AVM arteriovenous malformation, F female, GBM glioblastoma multiforme, M male, VS vestibular schwannoma.
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